According to a filing with the Singapore Exchange on Wednesday, Chan Huap's (SGX:C33) wholly-owned subsidiary, CH Biovest, saw the Court of Appeal in Singapore dismiss its appeal regarding a litigation case.
The company has now been ordered the costs of the appeal to be fixed at SG$60,000, payable to the claimants, envy asset.
In an earlier filing, the company was found liable to pay SG$2.3 million to Envy Asset, plus interest.
The suit was filed against Biovest in relation to profits paid out by Envy Asset in 2019 and 2020. Envy Asset paid Bioinvest around SG$2.3 million in order to put the assets beyond the reach of Envy Asset's creditors.
A Singaporean high court found Bioinvest is liable to pay the amount plus interest payable from Dec. 26, 2022, the date of the first demand of repayment.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。